1. Home
  2. HYT vs PHAR Comparison

HYT vs PHAR Comparison

Compare HYT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Corporate High Yield Fund Inc.

HYT

Blackrock Corporate High Yield Fund Inc.

HOLD

Current Price

$8.48

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$12.68

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYT
PHAR
Founded
2003
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HYT
PHAR
Price
$8.48
$12.68
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$38.33
AVG Volume (30 Days)
738.4K
10.3K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
9.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.04
Revenue Next Year
N/A
$2.51
P/E Ratio
N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$8.22
$9.54
52 Week High
$9.88
$21.34

Technical Indicators

Market Signals
Indicator
HYT
PHAR
Relative Strength Index (RSI) 41.69 32.76
Support Level $8.22 $11.43
Resistance Level $8.70 $13.44
Average True Range (ATR) 0.06 0.50
MACD -0.02 -0.12
Stochastic Oscillator 31.25 20.11

Price Performance

Historical Comparison
HYT
PHAR

About HYT Blackrock Corporate High Yield Fund Inc.

BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide shareholders with current income. The trust's secondary investment objective is to provide shareholders with capital appreciation. Under Normal market conditions, the fund invests at least 80% of its net assets in high-yield securities of corporate issuers and derivatives that provide exposure to those securities or related market risk factors.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: